Presatovir

	Presatovir Presatovir (GS-5806) is an antiviral drug which was developed as a treatment for respiratory syncytial virus. It acts as a fusion inhibitor, and has shown promising results in Phase II clinical trials. See also * Palivizumab * Lumicitabine * Ziresovir Ziresovir (RO-0529, AK0529) is an antiviral drug which was developed as a treatment for respiratory syncytial virus. It acts as a fusion inhibitor, and has shown good results in Phase II and III clinical trials. See also * Palivizumab * Pres ... References Anti–RNA virus drugs Antiviral drugs {{antiinfective-drug-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu]
picture info	Respiratory Syncytial Virus Respiratory syncytial virus (RSV), also called human respiratory syncytial virus (hRSV) and human orthopneumovirus, is a common, contagious virus that causes infections of the respiratory tract. It is a negative-sense, single-stranded RNA virus. Its name is derived from the large cells known as ''syncytia'' that form when infected cells fuse. RSV is the single most common cause of respiratory hospitalization in infants, and reinfection remains common in later life: it is a notable pathogen in all age groups. Infection rates are typically higher during the cold winter months, causing bronchiolitis in infants, common colds in adults, and more serious respiratory illnesses such as pneumonia in the elderly and immunocompromised. RSV can cause outbreaks both in the community and in hospital settings. Following initial infection via the eyes or nose, the virus infects the epithelial cells of the upper and lower airway, causing inflammation, cell damage, and airway obstruction. A variet ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu]
	Lumicitabine Lumicitabine (ALS-8176) is an antiviral drug which was developed as a treatment for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). It acts as an RNA polymerase inhibitor. While it showed promise in early clinical trials, poor results in Phase IIb trials led to it being discontinued from development for treatment of RSV. Research continues to determine whether it may be useful for the treatment of diseases caused by other RNA viruses, and it has been found to show activity against Nipah virus. See also * Palivizumab * Presatovir * Ziresovir Ziresovir (RO-0529, AK0529) is an antiviral drug which was developed as a treatment for respiratory syncytial virus. It acts as a fusion inhibitor, and has shown good results in Phase II and III clinical trials. See also * Palivizumab * Pres ... References Anti–RNA virus drugs Antiviral drugs Tetrahydrofurans Pyrimidines Abandoned drugs {{antiinfective-drug-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu]
	Ziresovir Ziresovir (RO-0529, AK0529) is an antiviral drug which was developed as a treatment for respiratory syncytial virus. It acts as a fusion inhibitor, and has shown good results in Phase II and III clinical trials. See also * Palivizumab * Presatovir * Lumicitabine Lumicitabine (ALS-8176) is an antiviral drug which was developed as a treatment for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). It acts as an RNA polymerase inhibitor. While it showed promise in early clinical trials, poor ... References Anti–RNA virus drugs Antiviral drugs Sulfones Oxetanes Benzothiazepines Quinazolines Amines {{antiinfective-drug-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu]
picture info	Antiviral Drug Antiviral drugs are a class of medication used for treating viral infections. Most antivirals target specific viruses, while a broad-spectrum antiviral is effective against a wide range of viruses. Unlike most antibiotics, antiviral drugs do not destroy their target pathogen; instead they inhibit its development. Antiviral drugs are one class of antimicrobials, a larger group which also includes antibiotic (also termed antibacterial), antifungal and antiparasitic drugs, or antiviral drugs based on monoclonal antibodies. Most antivirals are considered relatively harmless to the host, and therefore can be used to treat infections. They should be distinguished from viricides, which are not medication but deactivate or destroy virus particles, either inside or outside the body. Natural viricides are produced by some plants such as eucalyptus and Australian tea trees. Medical uses Most of the antiviral drugs now available are designed to help deal with HIV, herpes viruses, th ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu]
picture info	Clinical Trial Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison. Clinical trials generate data on dosage, safety and efficacy. They are conducted only after they have received health authority/ethics committee approval in the country where approval of the therapy is sought. These authorities are responsible for vetting the risk/benefit ratio of the trial—their approval does not mean the therapy is 'safe' or effective, only that the trial may be conducted. Depending on product type and development stage, investigators initially enroll volunteers or patients into small pilot studies, and subsequently conduct progressively larger scale comparative studies. Clinical trials can vary i ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu]
	Palivizumab Palivizumab, sold under the brand name Synagis, is a monoclonal antibody produced by recombinant DNA technology used to prevent severe disease caused by respiratory syncytial virus (RSV) infections. It is recommended for infants at high-risk for RSV due to conditions such as prematurity or other medical problems including heart or lung diseases. The most common side effects include fever and rash. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged. Palivizumab is a humanized monoclonal antibody (IgG) directed against an epitope in the A antigenic site of the F protein of RSV. In two phase III clinical trials in the pediatric population, palivizumab reduced the risk of hospitalization due to RSV infection by 55% and 45%. Palivizumab is dosed once a month via intramuscular (IM) injection, to be administered throughout the duration of the RSV season, which in based on past trends has started in Mi ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu]